A single nucleotide polymorphism in the coding region of PGC-1α is a male-specific modifier...

Background Genetic modifiers are important clues for the identification of therapeutic targets in neurodegenerative diseases. Huntington disease (HD) is one of the most common autosomal...

Is this the drug answer to Alzheimer’s and Huntington’s disease?

With a $44 million investment, a group of investors is betting that a Stanford University spinout has a drug that potentially could interfere earlier...

Accentuating the positive: Olympic medalist Sarah Winckless’s strategy against Huntington’s disease

  As a bronze medalist in rowing in the 2004 Summer Olympics in Athens and chair of the highly successful British athletes’ commission in the...

Drosophila center hits historic milestone with chromosome deletions

Indiana University’s Bloomington Drosophila Stock Center, a clearinghouse for genetically defined lines of fruit flies that serves scientists in 2,600 laboratories worldwide, has reached...

Discovery could aid in development of treatments for fatal brain disease

Huntington's disease is an inherited brain disorder that is uniformly fatal, but researchers at Johns Hopkins believe they have made a big discovery about...

First patients dosed with ‘gene silencing’ drug for Huntington’s disease

This article was first published at https://medicalxpress.com The trial aims to test the safety of an experimental drug known as ISIS-HTTRx, discovered and developed by Isis...

Proteomic analysis of wild-type and mutant huntingtin associated proteins in mouse brains identifies unique...

  Huntington disease (HD) is a neurodegenerative disorder caused by a CAG repeat amplification in the gene huntingtin (HTT), which is reflected by a polyglutamine...

Huntington’s disease modifier genes – the role of Mlh1

Introduction: Huntington’s disease (HD) is a dominantly inherited disorder. HD is a neurodegenerative disease, with cognitive decline, behavioral symptoms and chorea. The Huntingtin gene (HTT) normally...

Isis Pharmaceuticals Initiates Clinical Study of ISIS-HTT Rx in Patients With Huntington’s Disease

First therapy designed to directly target the cause of disease Isis Earns $22 Million Milestone Payment from Roche Isis Pharmaceuticals, Inc.(NASDAQ: ISIS) today announced that it...
222,553FansLike
67,562FollowersFollow
32,600SubscribersSubscribe

Featured

Most Popular

Huntington’s Disease – Pipeline Review, H1 2014

Global Markets Direct’s, ‘Huntington's Disease - Pipeline Review, H1 2014’, provides an overview of the Huntington's Disease’s therapeutic pipeline.This report provides comprehensive information on...

Latest reviews

Caspase-6 does not contribute to the proteolysis of mutant huntingtin in...

  FUNDING STATEMENT This work was funded by the CHDI Foundation, a privately funded non-profit biomedical research organisation exclusively dedicated to discovering and developing therapeutics that...

Transcription Elongation and Tissue-Specific Somatic CAG Instability

Abstract The expansion of CAG/CTG repeats is responsible for many diseases, including Huntington's disease (HD) and myotonic dystrophy 1. CAG/CTG expansions are unstable in selective...

NOBEL PRIZE TO BRITON, JAPANESE FOR STEM CELL WORK

STOCKHOLM (AP) -- A British researcher and a Japanese scientist won the Nobel Prize in physiology or medicine on Monday for discovering that ordinary...

More News

0 Condivisioni